Poll: Are your patients requesting genetic testing?

Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.

Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.

A systematic review found transdermal nitroglycerin may modestly reduce hot flashes, but evidence remains limited.

The FDA approved the first generic of Climara Pro, a weekly estradiol/levonorgestrel patch for VMS and osteoporosis prevention in women with a uterus.

The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.

The Menopause Society's 2026 meeting in San Diego will tackle estrogen avoidance, cancer survivorship, mood, and sleep.

SWHR, ACOG, and WFRC called for sustained funding after a new women’s health executive order.

Real-world fezolinetant (Veozah) sleep data help ob-gyns counsel patients hesitant about hormone therapy, according to Marla Shapiro, CM, MDCM.